CNS Drugs

, Volume 15, Issue 12, pp 941–954

Third-Generation Antidepressants

Do They Offer Advantages Over the SSRIs?

Authors

  • James S. Olver
    • Department of PsychiatryUniversity of Melbourne, Austin & Repatriation Medical Centre
  • Graham D. Burrows
    • Department of PsychiatryUniversity of Melbourne, Austin & Repatriation Medical Centre
    • Department of PsychiatryUniversity of Melbourne, Austin & Repatriation Medical Centre
Review Article

DOI: 10.2165/00023210-200115120-00004

Cite this article as:
Olver, J.S., Burrows, G.D. & Norman, T.R. CNS Drugs (2001) 15: 941. doi:10.2165/00023210-200115120-00004

Abstract

Third-generation antidepressants are a group of antidepressant agents of variable action, not confined to serotonin reuptake inhibition. These agents include venlafaxine, reboxetine, nefazodone and mirtazapine. Claims have been made for these agents in terms of improved efficacy, faster speed of onset of effect and greater safety in the treatment of depression compared with previous medications, such as the selective serotonin reuptake inhibitors (SSRIs). This article reviews the evidence for these improvements.

Thirty active comparator studies were reviewed involving the third-generation antidepressant agents. While there were isolated reports of improvements over comparator agents for venlafaxine, reboxetine and mirtazepine, there were no convincing differences between third-generation agents and comparators in terms of overall efficacy, relapse prevention and speed of onset. The third-generation antidepressants were, however, of equivalent safety to SSRIs and maintained improvements in safety over first-generation agents

Copyright information

© Adis International Limited 2001